TXG vs ZBH
10x Genomics, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
TXG
10x Genomics, Inc.
53
Watch
VS
| Metric | TXG | ZBH |
|---|
| AI Score |
53
|
69
|
| Price |
$58.48
|
$97.22
|
| P/E Ratio |
-99.12×
|
23.54×
|
| ROE |
-5.5%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.0%
|
69.9%
|
| Debt / Equity |
0.10×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
79.3
|
63.1
|
| Beta |
2.039
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for TXG versus ZBH.
ZBH leads by 16 points.
ZBH scores 69/100 (Buy) versus TXG at 53/100 (Watch).
TXG Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -4.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -9.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -4.3% YoY -- this is not a growth story right now — Growth
- RSI at 79 is in overbought territory — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical